These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11103052)

  • 21. Atorvastatin for protease inhibitor-related hyperlipidaemia.
    Murillas J; Martín T; Ramos A; Portero JL
    AIDS; 1999 Jul; 13(11):1424-5. PubMed ID: 10449305
    [No Abstract]   [Full Text] [Related]  

  • 22. Efficacy and tolerability of pravastatin for the treatment of HIV-1 protease inhibitor-associated hyperlipidaemia: a pilot study.
    Baldini F; Di Giambenedetto S; Cingolani A; Murri R; Ammassari A; De Luca A
    AIDS; 2000 Jul; 14(11):1660-2. PubMed ID: 10983656
    [No Abstract]   [Full Text] [Related]  

  • 23. Efficacy and safety of atazanavir-ritonavir plus abacavir-lamivudine or tenofovir-emtricitabine in patients with hyperlipidaemia switched from a stable protease inhibitor-based regimen including one thymidine analogue.
    Calza L; Manfredi R; Colangeli V; Pocaterra D; Rosseti N; Pavoni M; Chiodo F
    AIDS Patient Care STDS; 2009 Sep; 23(9):691-7. PubMed ID: 19739937
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hyperlipidemia associated with protease inhibitor therapy.
    Echevarria KL; Hardin TC; Smith JA
    Ann Pharmacother; 1999; 33(7-8):859-63. PubMed ID: 10466916
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protease inhibitor therapy-associated lipodystrophy, hypertriglyceridaemia and diabetes mellitus.
    Paparizos VA; Kyriakis KP; Botsis C; Papastamopoulos V; Hadjivassiliou M; Stavrianeas NG
    AIDS; 2000 May; 14(7):903-5. PubMed ID: 10839604
    [No Abstract]   [Full Text] [Related]  

  • 26. Marked hyperlipidaemia on ritonavir therapy.
    Sullivan AK; Nelson MR
    AIDS; 1997 Jun; 11(7):938-9. PubMed ID: 9189227
    [No Abstract]   [Full Text] [Related]  

  • 27. Outcomes of switch to atazanavir-containing combination antiretroviral therapy in HIV-1-infected patients with hyperlipidemia.
    Lu CL; Lin YH; Wong WW; Lin HH; Ho MW; Wang NC; Hsieh SM; Sheng WH; Hung CC; Chen MY
    J Microbiol Immunol Infect; 2011 Aug; 44(4):258-64. PubMed ID: 21524961
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV-protease inhibitors.
    Di Perri G; Del Bravo P; Concia E
    N Engl J Med; 1998 Sep; 339(11):773-4; author reply 774. PubMed ID: 9742031
    [No Abstract]   [Full Text] [Related]  

  • 29. Tuberous and tendinous xanthomata secondary to ritonavir-associated hyperlipidemia.
    Brown CA; Lesher JL; Peterson CM
    J Am Acad Dermatol; 2005 May; 52(5 Suppl 1):S86-9. PubMed ID: 15858517
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Relative effects of insulin resistance and protease inhibitor treatment on lipid and lipoprotein metabolism in HIV-infected patients.
    Beatty G; Chu J; Kulkarni K; Lipshutz G; Khalili M; Abbasi F; Stansell J; Reaven GM
    HIV Clin Trials; 2004; 5(6):383-91. PubMed ID: 15682351
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Lipid lowering therapy in patients with HIV infection.
    McBride M; Chin MT; Lee SM; Kelly B
    Lancet; 1998 Nov; 352(9142):1782-3. PubMed ID: 9848377
    [No Abstract]   [Full Text] [Related]  

  • 32. A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors.
    Carr A; Samaras K; Burton S; Law M; Freund J; Chisholm DJ; Cooper DA
    AIDS; 1998 May; 12(7):F51-8. PubMed ID: 9619798
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Lipid disorders in antiretroviral-naive patients treated with lopinavir/ritonavir-based HAART: frequency, characterization and risk factors.
    Montes ML; Pulido F; Barros C; Condes E; Rubio R; Cepeda C; Dronda F; Antela A; Sanz J; Navas E; Miralles P; Berenguer J; Pérez S; Zapata A; González-García JJ; Peña JM; Vázquez JJ; Arribas JR
    J Antimicrob Chemother; 2005 May; 55(5):800-4. PubMed ID: 15761071
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Editorial comment: boosted PIs and metabolism--it's not just the ritonavir.
    Moyle GJ
    AIDS Read; 2005 Oct; 15(10):531. PubMed ID: 16265769
    [No Abstract]   [Full Text] [Related]  

  • 35. Left main coronary artery disease in a 40-year-old man receiving HIV protease inhibitors.
    Hayes P; Muller D; Kuchar D
    Aust N Z J Med; 2000 Feb; 30(1):92-3. PubMed ID: 10800890
    [No Abstract]   [Full Text] [Related]  

  • 36. Acute pancreatitis in HIV-infected patients: are etiologies changing since the introduction of protease inhibitor therapy?
    Bush ZM; Kosmiski LA
    Pancreas; 2003 Jul; 27(1):e1-5. PubMed ID: 12826911
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.
    de Luis DA; Bachiller P; Aller R; Eiros Bouza J; Izaola O
    Nutrition; 2003 Oct; 19(10):903-4. PubMed ID: 14559329
    [No Abstract]   [Full Text] [Related]  

  • 38. Ritonavir, triglycerides, and pancreatitis.
    Perry RC; Cushing HE; Deeg MA; Prince MJ
    Clin Infect Dis; 1999 Jan; 28(1):161-2. PubMed ID: 10028103
    [No Abstract]   [Full Text] [Related]  

  • 39. Is treatment with ritonavir a risk factor for myocardial infarction in HIV-infected patients?
    Eriksson U; Opravil M; Amann FW; Schaffner A
    AIDS; 1998 Oct; 12(15):2079-80. PubMed ID: 9814881
    [No Abstract]   [Full Text] [Related]  

  • 40. [Effects of high grade antiretroviral therapy on body fat distribution and metabolism].
    Schwenk A
    Zentralbl Gynakol; 1999; 121(11):552-3. PubMed ID: 10612226
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.